Neurocrine Biosciences (NBIX)
(Real Time Quote from BATS)
$147.22 USD
+3.09 (2.14%)
Updated Aug 8, 2024 01:31 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 201 - 220 ( 312 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
As Commercial Advances Continue, Believe CAH Data Can Be Meaningful Catalyst; Reit Buy and $102PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Continue to Believe 2019 Value Proposition Is Attractive; Reit Buy and $102 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Our Thoughts Following the Miss in Tourette Syndrome T-Force Gold Trial; Lowering PT to $102
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Momentum on Multiple Fronts; Reit Buy and Raising PT to $162
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Utilizing Growth of Ingrezza Revenue to Invest in Ingrezza
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
2018 Ought to Be a Catalyst-Filled Year; Reit Buy and $139PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Ingrezza Strength Reaffirms Our Bull Case; Reit Buy and Raising PT to $139
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Strong Ingrezza Launch Lifts the Tone for Quarters Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Strong Ingrezza Launch Lifts the Tone for Quarters Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Moderating Near-Term Forecasts Following Physician Feedback; Long-Term Bullishness Intact, Reit Buy and $130 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A